{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:03:52Z","timestamp":1740135832535,"version":"3.37.3"},"reference-count":55,"publisher":"Informa UK Limited","issue":"11","funder":[{"name":"Carolinas Myeloma Research Fund"},{"name":"Heinemann Foundation of Charlotte"},{"name":"the Freedland Fund"},{"DOI":"10.13039\/100005189","name":"the Leukemia Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NCI","award":["5R01CA201634"],"award-info":[{"award-number":["5R01CA201634"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2020,9,18]]},"DOI":"10.1080\/10428194.2020.1786558","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T11:15:36Z","timestamp":1593861336000},"page":"2549-2560","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Management of newly diagnosed transplant ineligible multiple myeloma"],"prefix":"10.1080","volume":"61","author":[{"given":"Shebli","family":"Atrash","sequence":"first","affiliation":[{"name":"Department of Hematologic Oncology & Blood Disorders, Division of Plasma Cell Disorders, Levine Cancer Institute\/Atrium Health, Charlotte, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology & Blood Disorders, Division of Plasma Cell Disorders, Levine Cancer Institute\/Atrium Health, Charlotte, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology & Blood Disorders, Division of Plasma Cell Disorders, Levine Cancer Institute\/Atrium Health, Charlotte, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology & Blood Disorders, Division of Plasma Cell Disorders, Levine Cancer Institute\/Atrium Health, Charlotte, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology & Blood Disorders, Division of Plasma Cell Disorders, Levine Cancer Institute\/Atrium Health, Charlotte, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,7,4]]},"reference":[{"unstructured":"SEER Cancer Stat Facts: myeloma. Bethesda (MD): National Cancer Institute; 2019; [cited 2019 Feb 19]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html","key":"CIT0001"},{"unstructured":"CIBMTR\u00ae (Center for International Blood and Marrow Transplant Research\u00ae); 2019; [cited 2019 Feb 19]. Available from: https:\/\/www.cibmtr.org\/ReferenceCenter\/SlidesReports\/SummarySlides\/pages\/index.aspx","key":"CIT0002"},{"doi-asserted-by":"publisher","key":"CIT0003","DOI":"10.1002\/ajh.23753"},{"doi-asserted-by":"publisher","key":"CIT0004","DOI":"10.1056\/NEJMoa1611750"},{"doi-asserted-by":"publisher","key":"CIT0005","DOI":"10.1056\/NEJMoa1402888"},{"doi-asserted-by":"publisher","key":"CIT0006","DOI":"10.1016\/j.bbmt.2017.12.316"},{"doi-asserted-by":"publisher","key":"CIT0007","DOI":"10.1016\/S1470-2045(15)00389-7"},{"doi-asserted-by":"publisher","key":"CIT0008","DOI":"10.1056\/NEJMoa022340"},{"doi-asserted-by":"publisher","key":"CIT0009","DOI":"10.1056\/NEJM199607113350204"},{"doi-asserted-by":"publisher","key":"CIT0010","DOI":"10.1182\/blood-2014-12-615187"},{"doi-asserted-by":"publisher","key":"CIT0011","DOI":"10.1182\/blood-2011-06-358812"},{"doi-asserted-by":"publisher","key":"CIT0012","DOI":"10.1038\/s41408-019-0205-9"},{"doi-asserted-by":"publisher","key":"CIT0013","DOI":"10.1016\/j.clml.2018.06.018"},{"doi-asserted-by":"publisher","key":"CIT0014","DOI":"10.1016\/S0140-6736(07)61537-2"},{"doi-asserted-by":"publisher","key":"CIT0015","DOI":"10.1056\/NEJMoa0801479"},{"doi-asserted-by":"publisher","key":"CIT0016","DOI":"10.1182\/blood-2015-11-679415"},{"doi-asserted-by":"publisher","key":"CIT0017","DOI":"10.1007\/s00277-016-2901-x"},{"doi-asserted-by":"publisher","key":"CIT0018","DOI":"10.1056\/NEJMoa1112704"},{"doi-asserted-by":"publisher","key":"CIT0019","DOI":"10.1056\/NEJMoa1402551"},{"doi-asserted-by":"publisher","key":"CIT0020","DOI":"10.1111\/bjh.15261"},{"doi-asserted-by":"publisher","key":"CIT0021","DOI":"10.1016\/j.clml.2017.03.045"},{"doi-asserted-by":"crossref","unstructured":"Leleu X, Fouquet G, Karlin L, et\u00a0al. Multicentric open label phase 1\/2 carfilzomib weekly with melphalan and prednisone in non transplant eligible newly diagnosed myeloma (eNDMM): IFM2012-03. Clin Cancer Res. 2019;25(14):4224\u20134230.","key":"CIT0022","DOI":"10.1158\/1078-0432.CCR-18-3642"},{"doi-asserted-by":"publisher","key":"CIT0023","DOI":"10.1056\/NEJMoa1817249"},{"doi-asserted-by":"publisher","key":"CIT0024","DOI":"10.1056\/NEJMoa1714678"},{"doi-asserted-by":"publisher","key":"CIT0025","DOI":"10.1016\/0021-9681(87)90171-8"},{"doi-asserted-by":"publisher","key":"CIT0026","DOI":"10.1182\/blood-2005-05-2004"},{"doi-asserted-by":"publisher","key":"CIT0027","DOI":"10.1016\/0021-9681(74)90017-4"},{"doi-asserted-by":"publisher","key":"CIT0028","DOI":"10.3324\/haematol.2016.162693"},{"doi-asserted-by":"publisher","key":"CIT0029","DOI":"10.1038\/bjc.2014.307"},{"doi-asserted-by":"publisher","key":"CIT0030","DOI":"10.1517\/14656566.2013.803068"},{"doi-asserted-by":"publisher","key":"CIT0031","DOI":"10.1016\/S0140-6736(06)68338-4"},{"doi-asserted-by":"publisher","key":"CIT0032","DOI":"10.1182\/blood.V110.11.75.75"},{"doi-asserted-by":"publisher","key":"CIT0033","DOI":"10.1016\/S1470-2045(11)70081-X"},{"doi-asserted-by":"publisher","key":"CIT0034","DOI":"10.1200\/JCO.2007.14.1853"},{"doi-asserted-by":"publisher","key":"CIT0035","DOI":"10.1023\/A:1011141009812"},{"unstructured":"Approved Risk Evaluation and Mitigation Strategies (REMS). Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm?event=IndvRemsDetails.page&REMS=58","key":"CIT0036"},{"doi-asserted-by":"publisher","key":"CIT0037","DOI":"10.1056\/NEJMoa1114138"},{"doi-asserted-by":"publisher","key":"CIT0038","DOI":"10.1182\/blood-2007-06-097444"},{"doi-asserted-by":"publisher","key":"CIT0039","DOI":"10.1200\/JCO.1998.16.12.3832"},{"doi-asserted-by":"publisher","key":"CIT0040","DOI":"10.1182\/blood-2008-07-169565"},{"doi-asserted-by":"publisher","key":"CIT0041","DOI":"10.1182\/blood-2008-04-149427"},{"doi-asserted-by":"publisher","key":"CIT0042","DOI":"10.1182\/blood-2009-08-237974"},{"doi-asserted-by":"publisher","key":"CIT0043","DOI":"10.1182\/blood-2011-02-338665"},{"doi-asserted-by":"publisher","key":"CIT0044","DOI":"10.1016\/S1470-2045(10)70187-X"},{"doi-asserted-by":"publisher","key":"CIT0045","DOI":"10.1182\/blood-2014-12-613927"},{"doi-asserted-by":"publisher","key":"CIT0046","DOI":"10.1182\/blood-2017-07-795047"},{"doi-asserted-by":"publisher","key":"CIT0047","DOI":"10.1182\/blood-2015-08-662627"},{"doi-asserted-by":"publisher","key":"CIT0048","DOI":"10.1182\/blood-2018-99-111796"},{"doi-asserted-by":"publisher","key":"CIT0049","DOI":"10.1200\/JCO.2010.29.8216"},{"doi-asserted-by":"publisher","key":"CIT0050","DOI":"10.1001\/jama.1969.03160090040009"},{"doi-asserted-by":"publisher","key":"CIT0051","DOI":"10.2217\/fon-2019-0013"},{"key":"CIT0052","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood.V130.Suppl_1.744.744","volume":"130","author":"Larocca A","year":"2017","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"CIT0053","DOI":"10.1001\/jamaoncol.2015.2010"},{"doi-asserted-by":"publisher","key":"CIT0054","DOI":"10.1038\/bcj.2015.62"},{"doi-asserted-by":"publisher","key":"CIT0055","DOI":"10.1182\/blood-2018-99-114668"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2020.1786558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T10:59:45Z","timestamp":1620557985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2020.1786558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,4]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,9,18]]}},"alternative-id":["10.1080\/10428194.2020.1786558"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2020.1786558","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"type":"print","value":"1042-8194"},{"type":"electronic","value":"1029-2403"}],"subject":[],"published":{"date-parts":[[2020,7,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}